TrialAnnals of the rheumatic diseases2017

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).

Josef S Smolen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.